Reopro Ischemic Stroke Trial Halted
This article was originally published in The Pink Sheet Daily
Executive Summary
Centocor and Lilly are permanently discontinuing a Phase III study of Reopro (abciximab) for acute ischemic stroke after the study's independent Safety & Efficacy Monitoring Committee confirmed concerns about intracranial hemorrhage that previously prompted the firms to suspend enrollment